Infecção pelo vírus sincicial respiratório

Novos compostos antivirais

Devido à escassez de evidências para a eficácia da ribavirina (a única terapia aprovada para o VSR), uma terapia com eficácia clara seria uma inovação bem-vinda. Vários compostos antivirais estão em estágio de desenvolvimento clínico.[142]Huntjens DRH, Ouwerkerk-Mahadevan S, Brochot A, et al. Population pharmacokinetic modeling of JNJ-53718678, a novel fusion inhibitor for the treatment of respiratory syncytial virus: results from a phase I, double-blind, randomized, placebo-controlled first-in-human study in healthy adult subjects. Clin Pharmacokinet. 2017 Nov;56(11):1331-42. http://www.ncbi.nlm.nih.gov/pubmed/28238203?tool=bestpractice.com Eles incluem terapias que bloqueiam a proteína de fusão do VSR (VSR-F), inibindo a polimerase viral (VSR-L) ou outras proteínas virais centrais (VSR-N, VSR-M2). Essas terapias estão em estágios variados de desenvolvimento clínico.[30]Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019 Sep 10;366:l5021. https://www.doi.org/10.1136/bmj.l5021 http://www.ncbi.nlm.nih.gov/pubmed/31506273?tool=bestpractice.com [86]Coultas JA, Smyth R, Openshaw PJ. Respiratory syncytial virus (RSV): a scourge from infancy to old age. Thorax. 2019 Oct;74(10):986-93. https://www.doi.org/10.1136/thoraxjnl-2018-212212 http://www.ncbi.nlm.nih.gov/pubmed/31383776?tool=bestpractice.com [143]DeVincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med. 2014 Aug 21;371(8):711-22. https://www.nejm.org/doi/full/10.1056/nejmoa1401184 http://www.ncbi.nlm.nih.gov/pubmed/25140957?tool=bestpractice.com [144]Mazur NI, Terstappen J, Baral R, et al. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infect Dis. 2023 Jan;23(1):e2-e21. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00291-2/fulltext http://www.ncbi.nlm.nih.gov/pubmed/35952703?tool=bestpractice.com ​​​